{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,3,9]],"date-time":"2024-03-09T00:36:21Z","timestamp":1709944581125},"reference-count":23,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,3,7]]},"DOI":"10.7759\/cureus.55764","type":"journal-article","created":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T07:47:26Z","timestamp":1709884046000},"source":"Crossref","is-referenced-by-count":0,"title":["Boosting Vaccine Response in Autoimmune Rheumatic Disease Patients With Inadequate Seroconversion: An Analysis of the Immunogenicity of Vector-Based and Inactivated Vaccines"],"prefix":"10.7759","author":[{"given":"Anuroopa","family":"Vijayan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aswathy","family":"Sukumaran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aby","family":"Paul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sakir","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pankti","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manju","family":"Mohanan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Santhosh","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sreekumar","family":"Easwaran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Padmanabha","family":"Shenoy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.10.049","article-title":"Case study: prolonged infectious SARS-CoV-2 shedding from an asymptomatic immunocompromised individual with cancer","volume":"183","author":"Avanzato VA","year":"2020","unstructured":"Avanzato VA, Matson MJ, Seifert SN, et al.. Case study: prolonged infectious SARS-CoV-2 shedding from an asymptomatic immunocompromised individual with cancer. Cell. 2020, 183:1901-12. 10.1016\/j.cell.2020.10.049","journal-title":"Cell"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cub.2021.06.049","article-title":"The origins and potential future of SARS-CoV-2 variants of concern in the evolving COVID-19 pandemic","volume":"31","author":"Otto SP","year":"2021","unstructured":"Otto SP, Day T, Arino J, et al.. The origins and potential future of SARS-CoV-2 variants of concern in the evolving COVID-19 pandemic. Curr Biol. 2021, 31:918-29. 10.1016\/j.cub.2021.06.049","journal-title":"Curr Biol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2021.08.010","article-title":"Outcomes of COVID-19 in patients with rheumatoid arthritis: a multicenter research network study in the United States","volume":"51","author":"Raiker R","year":"2021","unstructured":"Raiker R, DeYoung C, Pakhchanian H, et al.. Outcomes of COVID-19 in patients with rheumatoid arthritis: a multicenter research network study in the United States. Semin Arthritis Rheum. 2021, 51:1057-66. 10.1016\/j.semarthrit.2021.08.010","journal-title":"Semin Arthritis Rheum"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2021.11.006","article-title":"Efficacy of booster doses in augmenting waning immune responses to COVID-19 vaccine in patients with cancer","volume":"40","author":"Shapiro LC","year":"2022","unstructured":"Shapiro LC, Thakkar A, Campbell ST, et al.. Efficacy of booster doses in augmenting waning immune responses to COVID-19 vaccine in patients with cancer. Cancer Cell. 2022, 40:3-5. 10.1016\/j.ccell.2021.11.006","journal-title":"Cancer Cell"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.889138","article-title":"SARS-CoV-2-mRNA booster vaccination reverses non-responsiveness and early antibody waning in immunocompromised patients - a phase four study comparing immune responses in patients with solid cancers, multiple myeloma and inflammatory bowel disease","volume":"13","author":"Wagner A","year":"2022","unstructured":"Wagner A, Garner-Spitzer E, Sch\u00f6tta A-M, et al.. SARS-CoV-2-mRNA booster vaccination reverses non-responsiveness and early antibody waning in immunocompromised patients - a phase four study comparing immune responses in patients with solid cancers, multiple myeloma and inflammatory bowel disease. Front Immunol. 2022, 13:889138. 10.3389\/fimmu.2022.889138","journal-title":"Front Immunol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221922","article-title":"Postvaccination antibody titres predict protection against COVID-19 in patients with autoimmune diseases: survival analysis in a prospective cohort","volume":"81","author":"Ahmed S","year":"2022","unstructured":"Ahmed S, Mehta P, Paul A, et al.. Postvaccination antibody titres predict protection against COVID-19 in patients with autoimmune diseases: survival analysis in a prospective cohort. Ann Rheum Dis. 2022, 81:868-74. 10.1136\/annrheumdis-2021-221922","journal-title":"Ann Rheum Dis"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(21)00593-3","article-title":"Response to additional COVID-19 vaccine doses in people who are immunocompromised: a rapid review","volume":"10","author":"Parker EPK","year":"2022","unstructured":"Parker EPK, Desai S, Marti M, et al.. Response to additional COVID-19 vaccine doses in people who are immunocompromised: a rapid review. Lancet Glob Health. 2022, 10:326-8. 10.1016\/S2214-109X(21)00593-3","journal-title":"Lancet Glob Health"},{"key":"ref8","unstructured":"People with certain medical conditions. (2023). Accessed. March 6, 2024: https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/need-extra-precautions\/people-with-medical-conditions.html."},{"key":"ref9","unstructured":"Interim recommendations on COVID-19 vaccination in autumn 2022 for the WHO European Region. conclusions and recommendations of the European Technical Advisory Group of Experts on Immunization: ad hoc virtual meeting, 5 July 2022. (2022). . (2024). Accessed: March 6, 2024: https:\/\/iris.who.int\/handle\/10665\/359622."},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221558","article-title":"Additional heterologous versus homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination: a randomised controlled trial","volume":"81","author":"Bonelli M","year":"2022","unstructured":"Bonelli M, Mrak D, Tobudic S, et al.. Additional heterologous versus homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination: a randomised controlled trial. Ann Rheum Dis. 2022, 81:687-94. 10.1136\/annrheumdis-2021-221558","journal-title":"Ann Rheum Dis"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-33036-y","article-title":"Heterologous vector versus homologous mRNA COVID-19 booster vaccination in non-seroconverted immunosuppressed patients: a randomized controlled trial","volume":"13","author":"Mrak D","year":"2022","unstructured":"Mrak D, Sieghart D, Simader E, et al.. Heterologous vector versus homologous mRNA COVID-19 booster vaccination in non-seroconverted immunosuppressed patients: a randomized controlled trial. Nat Commun. 2022, 13:5362. 10.1038\/s41467-022-33036-y","journal-title":"Nat Commun"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221496","article-title":"Inactivated vaccines may not provide adequate protection in immunosuppressed patients with rheumatic diseases","volume":"2021","author":"Shenoy P","year":"2021","unstructured":"Shenoy P, Ahmed S, Paul A, et al.. Inactivated vaccines may not provide adequate protection in immunosuppressed patients with rheumatic diseases. Ann Rheum Dis. 2021, 2021:221496. 10.1136\/annrheumdis-2021-221496","journal-title":"Ann Rheum Dis"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(21)00356-8","article-title":"Hybrid immunity versus vaccine-induced immunity against SARS-CoV-2 in patients with autoimmune rheumatic diseases","volume":"4","author":"Shenoy P","year":"2022","unstructured":"Shenoy P, Ahmed S, Paul A, et al.. Hybrid immunity versus vaccine-induced immunity against SARS-CoV-2 in patients with autoimmune rheumatic diseases. Lancet Rheumatol. 2022, 4:80-2. 10.1016\/S2665-9913(21)00356-8","journal-title":"Lancet Rheumatol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221824","article-title":"BNT162b2 mRNA COVID-19 vaccine and booster in patients with autoimmune rheumatic diseases: a national cohort study","volume":"81","author":"Bieber A","year":"2022","unstructured":"Bieber A, Sagy I, Novack L, et al.. BNT162b2 mRNA COVID-19 vaccine and booster in patients with autoimmune rheumatic diseases: a national cohort study. Ann Rheum Dis. 2022, 81:1028-35. 10.1136\/annrheumdis-2021-221824","journal-title":"Ann Rheum Dis"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.16775","article-title":"Efficiency of a boost with a third dose of anti-SARS-CoV-2 messenger RNA-based vaccines in solid organ transplant recipients","volume":"22","author":"Del Bello A","year":"2022","unstructured":"Del Bello A, Abravanel F, Marion O, et al.. Efficiency of a boost with a third dose of anti-SARS-CoV-2 messenger RNA-based vaccines in solid organ transplant recipients. Am J Transplant. 2022, 22:322-3. 10.1111\/ajt.16775","journal-title":"Am J Transplant"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2021.08.017","article-title":"A third injection of the BNT162b2 mRNA COVID-19 vaccine in kidney transplant recipients improves the humoral immune response","volume":"100","author":"Masset C","year":"2021","unstructured":"Masset C, Kerleau C, Garandeau C, et al.. A third injection of the BNT162b2 mRNA COVID-19 vaccine in kidney transplant recipients improves the humoral immune response. Kidney Int. 2021, 100:1132-5. 10.1016\/j.kint.2021.08.017","journal-title":"Kidney Int"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1002\/art.42109","article-title":"American College of Rheumatology Guidance for COVID-19 vaccination in patients with rheumatic and musculoskeletal diseases: version 4","volume":"74","author":"Curtis JR","year":"2022","unstructured":"Curtis JR, Johnson SR, Anthony DD, et al.. American College of Rheumatology Guidance for COVID-19 vaccination in patients with rheumatic and musculoskeletal diseases: version 4. Arthritis Rheumatol Hoboken NJ. 2022, 74:21-36. 10.1002\/art.42109","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2116414","article-title":"Homologous and heterologous Covid-19 booster vaccinations","volume":"386","author":"Atmar RL","year":"2022","unstructured":"Atmar RL, Lyke KE, Deming ME, et al.. Homologous and heterologous Covid-19 booster vaccinations. N Engl J Med. 2022, 386:1046-57. 10.1056\/NEJMoa2116414","journal-title":"N Engl J Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00094-0","article-title":"Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH- 001): a phase 4, non-inferiority, single blind, randomised study","volume":"399","author":"Costa Clemens SA","year":"2022","unstructured":"Costa Clemens SA, Weckx L, Clemens R, et al.. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH- 001): a phase 4, non-inferiority, single blind, randomised study. Lancet Lond Engl. 2022, 399:521-9. 10.1016\/S0140-6736(22)00094-0","journal-title":"Lancet Lond Engl"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.26046","article-title":"Assessment of heterologous and homologous boosting with inactivated COVID-19 vaccine at 3 months compared with homologous boosting of BNT162b2 at 6 months","volume":"5","author":"Low EV","year":"2022","unstructured":"Low EV, Tok PSK, Husin M, et al.. Assessment of heterologous and homologous boosting with inactivated COVID-19 vaccine at 3 months compared with homologous boosting of BNT162b2 at 6 months. JAMA Netw Open. 2022, 5:2226046. 10.1001\/jamanetworkopen.2022.26046","journal-title":"JAMA Netw Open"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-04120-y","article-title":"Immunogenicity and efficacy of heterologous ChAdOx1-BNT162b2 vaccination","volume":"600","author":"Pozzetto B","year":"2021","unstructured":"Pozzetto B, Legros V, Djebali S, et al.. Immunogenicity and efficacy of heterologous ChAdOx1-BNT162b2 vaccination. Nature. 2021, 600:701-6. 10.1038\/s41586-021-04120-y","journal-title":"Nature"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1186\/s12985-022-01858-3","article-title":"Seroconversion following the first, second, and third dose of SARS-CoV-2 vaccines in immunocompromised population: a systematic review and meta-analysis","volume":"19","author":"Mehrabi Nejad M-M","year":"2022","unstructured":"Mehrabi Nejad M-M, Shobeiri P, Dehghanbanadaki H, et al.. Seroconversion following the first, second, and third dose of SARS-CoV-2 vaccines in immunocompromised population: a systematic review and meta-analysis. Virol J. 2022, 19:132. 10.1186\/s12985-022-01858-3","journal-title":"Virol J"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keac298","article-title":"Safety of third-dose SARS-CoV-2 vaccination in patients with rheumatic and musculoskeletal disease. Rheumatol Oxf Engl","volume":"61","author":"Connolly CM","year":"2022","unstructured":"Connolly CM, Frey S, Chiang TP-Y, et al.. Safety of third-dose SARS-CoV-2 vaccination in patients with rheumatic and musculoskeletal disease. Rheumatol Oxf Engl. 2022, 61:302-4. 10.1093\/rheumatology\/keac298"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/218390-boosting-vaccine-response-in-autoimmune-rheumatic-disease-patients-with-inadequate-seroconversion-an-analysis-of-the-immunogenicity-of-vector-based-and-inactivated-vaccines","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T07:47:31Z","timestamp":1709884051000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/218390-boosting-vaccine-response-in-autoimmune-rheumatic-disease-patients-with-inadequate-seroconversion-an-analysis-of-the-immunogenicity-of-vector-based-and-inactivated-vaccines"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,7]]},"references-count":23,"URL":"https:\/\/doi.org\/10.7759\/cureus.55764","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3,7]]}}}